Evaluation of Ezetimibe and Atorvastatin Coadministration Versus Atorvastatin or Rosuvastatin Monotherapy in Japanese Patients With Hypercholesterolemia (Study P06027)(COMPLETED)

Organon and Co125 enrolled

Overview

The purpose of this study is to evaluate the efficacy and safety of atorvastatin 10 mg and ezetimibe 10 mg coadministration in Japanese participants with hypercholesterolemia whose low-density lipoprotein (LDL)-cholesterol levels have not reached the lipid management target value with atorvastatin 10 mg alone, versus increasing the dose of atorvastatin to 20 mg or changing to rosuvastatin 2.5 mg.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

125

Conditions

Primary Hypercholesterolemia

Interventions

EzetimibeDRUG

1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)

AtorvastatinDRUG

1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)

AtorvastatinDRUG

2 tablets of 10 mg daily for 12 weeks (Weeks 5-16)

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * atorvastatin 10 mg monotherapy for 4 weeks or longer before the start of the 4-week washout and low density lipoprotein-cholesterol (LDL-C) levels that had not reached the following lipid management target values during treatment: Category I (low-risk group) with no other risk factors - LDL-C \<160 mg/dL; Category II (mid-risk group) with 1-2 risk factors other than LDL-C levels - LDL-C \<140 mg/dL; Category III (high-risk group) with 3 or more other risk factors - LDL-C \<120 mg/dL; and for participants with history of coronary artery disease - LDL-C \<100 mg/dL. * outpatient men or women, age 20 years and older Exclusion Criteria: * fasted triglyceride level at the start of washout or treatment period exceeding 400 mg/dL. * homozygous familial hypercholesterolemia. * creatine phosphokinase (CPK) \>2 times the upper limit of normal (X ULN) at start of washout or treatment period. * glycosylated hemoglobin (HbA1c) \>=8％ at start of washout or treatment period. * severe hepatic function disorder, or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>2X ULN at start of washout or treatment period. * hypersensitivity to ezetimibe, atorvastatin, or rosuvastatin tablets. * pregnant or lactating * discontinued use of atorvastatin 10 mg for less than 4 weeks at start of treatment period (however, if participant had taken atorvastatin 10 mg before the test conducted at the start of the observation period, a period of discontinuation of 27 days is allowed.) * cyclosporine treatment * hyperlipidemia associated with hypothyroidism, obstructive gall bladder or biliary disease, chronic renal failure, and/or pancreatitis. * hyperlipidemia associated with drug administration that causes adverse serum lipid effects. * participation in a clinical study within 4 weeks of washout * cancer or cancer history within previous 5 years, except for successfully treated basal cell carcinoma of the skin.

Outcomes

Primary Outcomes

Percent Change in Low-Density Lipoprotein - Cholesterol (LDL-C) Values

LDL-C was measured before group study drug administration (Week 4, end of atorvastatin single therapy) and at the end of study drug administration (after 12 weeks of study drug treatment, or at discontinuation).

Time frame: End of Week 4 to Week 16 or discontinuation

Secondary Outcomes

Percent Change in LDL-C

LDL-C was measured at the start of the atorvastatin 10 mg treatment period (end of the washout period) and at the end of administration of the study drug (Week 16 or discontinuation).

Time frame: End of washout period to Week 16 or discontinuation

Number of Participants Whose LDL-C Levels Reached the Lipid Management Target Values

LDL-C was measured at the end of administration of the study drug (Week 16 or discontinuation). Target values: For participants with history of coronary artery disease: \<100 mg/dL; for participants with at least 3 cardiovascular (CV) risk factors: \<120 mg/dL; for participants with 1-2 CV risk factors: \<140 mg/dL; for participants with no CV risk factors: \<160 mg/dL.

Time frame: Week 16 or discontinuation

Percent Change in Total Lipids and High Sensitivity C-reactive Protein (Hs-CRP)

Total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), non-HDL-C, and hs-CRP were measured at 4 weeks after the start of the treatment period (after completion of administration of atorvastatin 10 mg alone) and at Week 16 or at discontinuation.

Time frame: End of Week 4 to Week 16 or discontinuation

Percent Change in Total Lipids and Hs-CRP

Total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), non-HDL-C, and hs-CRP were measured at the start of the treatment period (at start of administration of atorvastatin 10 mg alone) and at the end of study drug (Week 16 or discontinuation).

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.